Dosimetry for Proton Beam Therapy
Objective for MPD A.9.0 In conjunction with the medical community, develop protocols and techniques to be used to assess absorbed dose from high energy proton beams.
Background: A major advance in the beam treatment of cancers has been the development and adoption by the medical community of high energy proton beams (200+ MeV). While such beams are very expensive installations, the ability to focus proton beams on smaller domains of cancerous tissue has resulted in more efficacious patient treatment by minimizing potential radiation exposure to adjacent healthy tissue. Unlike electron beams or photon beams from isotopes or X-ray sources, proton beams do not attenuate as the distance from the source increases. Proton beams generate a Bragg peak concentrating the ionizing radiation at a distance from the source which is dependent upon the proton beam energy, as illustrated in Figure A.9.0.
The number of proton therapy centers has been increasing in the US, which increases the need for standardization of dosimetry in clinical protocols. The trend in proton therapy centers is shown in Figure A.9.1.
1 – In collaboration with proton beam cancer treatment centers, NIST and the ADCL’s should harmonize protocols for proton beam dose determinations. This will involve a selection of appropriate dosimeters for use in a clinical environment and studies amongst the existing proton beam treatment center as to the inter-center precision of such dosimeter systems.
1 – A minimum of 2 person-years per year over the next three year time period is required to launch into these objectives. Partnerships between NIST, ADCL’s and the medical community are essential in this area.